Tratamiento del Síndrome de Intestino Irritable

Introducción al Tratamiento

• El tratamiento del síndrome de intestino irritable debe comenzar con modificaciones dietéticas y de estilo de vida, seguido de terapias farmacológicas dirigidas a los síntomas predominantes y, en casos refractarios, considerar terapias psicológicas específicas, según la Sociedad Europea de Gastroenterología 1, 2]

Tratamiento de primera línea

• Se debe recomendar ejercicio físico regular a todos los pacientes con SII, según el Colegio Americano de Gastroenterología 3
• Todos los pacientes deben recibir asesoramiento dietético inicial, según el Colegio Americano de Gastroenterología 3
• La fibra soluble, como ispaghula, es efectiva para los síntomas globales y el dolor abdominal, comenzando con dosis bajas (3-4 g/día) y aumentando gradualmente para evitar la distensión, según el Colegio Americano de Gastroenterología 3
• Evitar la fibra insoluble (como salvado de trigo) ya que puede empeorar los síntomas, según el Colegio Americano de Gastroenterología 3
• Los probióticos pueden ser efectivos para los síntomas globales y el dolor abdominal; se recomienda probarlos durante 12 semanas y suspenderlos si no hay mejoría, según el Colegio Americano de Gastroenterología 3

Tratamiento farmacológico según el subtipo predominante

• La loperamida puede ser efectiva para la diarrea, pero debe titularse cuidadosamente para evitar efectos secundarios como dolor abdominal, distensión y estreñimiento, según el Colegio Americano de Gastroenterología 3
• Los antagonistas de los receptores 5-HT3 son eficaces como fármacos de segunda línea, según el Colegio Americano de Gastroenterología 3
• El antibiótico no absorbible rifaximina es eficaz como fármaco de segunda línea, aunque su efecto sobre el dolor abdominal es limitado, según el Colegio Americano de Gastroenterología 3
• Aumentar la fibra dietética o utilizar ispaghula/psyllium, según el Colegio Americano de Gastroenterología 3
• Ciertos antiespasmódicos pueden ser efectivos para los síntomas globales y el dolor abdominal, aunque pueden causar sequedad bucal, alteraciones visuales y mareos, según el Colegio Americano de Gastroenterología 3
• El aceite de menta puede ser útil como antiespasmódico, según la Sociedad Británica de Gastroenterología 2, 4

Tratamientos de segunda línea

• Los antidepresivos tricíclicos (ADT) son efectivos como fármacos de segunda línea para los síntomas globales y el dolor abdominal, según el Colegio Americano de Gastroenterología 3
• Se deben iniciar a dosis bajas (10 mg de amitriptilina una vez al día) y aumentar lentamente hasta un máximo de 30-50 mg una vez al día, según el Colegio Americano de Gastroenterología 3
• Los inhibidores selectivos de la recaptación de serotonina (ISRS) pueden ser efectivos como fármacos de segunda línea para los síntomas globales, según el Colegio Americano de Gastroenterología 3

Terapias psicológicas

• La terapia cognitivo-conductual específica para SII y la hipnoterapia dirigida al intestino deben considerarse cuando los síntomas persisten a pesar de los tratamientos de primera línea, según la Sociedad Británica de Gastroenterología 2, 4
• Las terapias psicológicas son especialmente recomendadas cuando los síntomas son refractarios al tratamiento farmacológico durante 12 meses, según la Sociedad Británica de Gastroenterología 4, 5

Consideraciones importantes

• Es fundamental explicar al paciente el diagnóstico de SII, su fisiopatología y la historia natural de la condición, según la Sociedad Británica de Gastroenterología 2
• Se debe introducir el concepto del SII como un trastorno de la interacción intestino-cerebro, junto con una explicación simple del eje intestino-cerebro y cómo este es afectado por la dieta, el estrés y las respuestas cognitivas, conductuales y emocionales a los síntomas, según la Sociedad Británica de Gastroenterología 2
• Revisar la eficacia después de 3 meses de tratamiento y suspender si no hay respuesta, según la Sociedad Británica de Gastroenterología 4, 5
• Los ADT deben continuarse durante al menos 6 meses si el paciente reporta respuesta sintomática, según la Sociedad Británica de Gastroenterología 4

Pitfalls y precauciones

• Evitar investigaciones exhaustivas una vez establecido el diagnóstico de SII, según la Sociedad Europea de Gastroenterología 1
• No recomendar dietas de eliminación basadas en anticuerpos IgG, según el Colegio Americano de Gastroenterología 3
• No recomendar una dieta libre de gluten a menos que haya evidencia de enfermedad celíaca, según el Colegio Americano de Gastroenterología 3
• Reconocer la frecuente comorbilidad con trastornos de salud mental y considerar la derivación a especialistas cuando sea necesario, según la Sociedad Europea de Gastroenterología 1

Treatment of Irritable Bowel Syndrome

First-Line Treatments

• Consider symptom monitoring using a diary to help identify possible triggers in patients with IBS, as recommended by the American Gastroenterological Association 6

Pharmacological Treatment Based on Predominant Symptoms

• Loperamide (2-4 mg, up to four times daily) can reduce loose stools, urgency, and fecal soiling in patients with IBS-D, according to the American Gastroenterological Association 6
• Antispasmodics (anticholinergics) are effective for pain, particularly when symptoms are exacerbated by meals in patients with IBS, as stated by the American Gastroenterological Association 6
• Consider cholestyramine for patients with cholecystectomy or suspected bile acid malabsorption, as recommended by the American Gastroenterological Association 6
• Increase dietary fiber (25 g/day) or use ispaghula/psyllium for patients with IBS-C, according to the American Gastroenterological Association 6

Second-Line Treatments

• Tricyclic antidepressants (TCAs) are effective for global symptoms and abdominal pain, particularly if pain is frequent or severe, in patients with IBS, as stated by the American Gastroenterological Association 6
• Cognitive-behavioral therapy specific for IBS is an effective option for patients with persistent symptoms, as recommended by the American Gastroenterological Association 6
• Dynamic (interpersonal) psychotherapy is a beneficial approach for patients who relate symptom exacerbations to stressors, have associated anxiety or depression, or have symptoms of relatively short duration, according to the American Gastroenterological Association 6
• Stress management/relaxation techniques are particularly beneficial for patients who experience waxing and waning symptoms rather than chronic pain, as stated by the American Gastroenterological Association 6

Treatment of IBS with Mixed Constipation and Diarrhea Symptoms

First-Line Approaches

• The American Gastroenterological Association recommends tricyclic antidepressants (TCAs) as the most effective first-line pharmacological treatment for patients with mixed IBS (IBS-M), starting with low-dose amitriptyline (10 mg once daily) and gradually titrating to 30-50 mg once daily 7, 8

Pharmacological Treatment for Pain

• Antispasmodics (particularly those with anticholinergic properties) can be effective for reducing abdominal pain and global symptoms, as suggested by the European Society of Gastroenterology 9, 10

Second-Line Pharmacological Treatments

• The American College of Gastroenterology recommends TCAs as the most effective drugs for treating IBS with mixed symptoms, with a strength of evidence rated as high 9, 10
• Selective Serotonin Reuptake Inhibitors (SSRIs) may be an effective alternative when TCAs are not tolerated, with a lower side effect profile compared to TCAs, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 7, 8, 11

Symptom-Specific Management for Alternating Symptoms

• Loperamide (2-4 mg, up to four times daily) can reduce stool frequency and urgency in patients with diarrhea episodes, as recommended by the World Gastroenterology Organisation 11, 9, 10
• 5-HT3 receptor antagonists (ondansetron titrated from 4 mg once daily to maximum 8 mg three times daily) are effective second-line options for diarrhea episodes, with a moderate strength of evidence 7, 8
• Linaclotide, a guanylate cyclase-C agonist, is an effective second-line drug for constipation episodes, though diarrhea is a common side effect, as reported by the American Gastroenterological Association 7, 8

Psychological Treatments

• Cognitive-behavioral therapy, dynamic psychotherapy, and hypnotherapy are effective for reducing abdominal pain and diarrhea in patients with IBS, particularly those who relate symptom exacerbations to stressors or have associated anxiety/depression, as suggested by the European Society of Gastroenterology 11

Common Pitfalls and Caveats

• Symptom monitoring using a diary can help identify triggers and guide treatment choices, with a high strength of evidence, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 11
• Recognize that many treatments have been studied in specific IBS subtypes, not specifically in mixed IBS, with a moderate strength of evidence, as reported by the American College of Gastroenterology 7, 8

Treatment of IBS with Constipation

First-Line Treatment Approach

• The American Gastroenterological Association recommends regular physical exercise to all IBS-C patients as this improves global symptoms and should be the foundation of treatment 12
• The American Gastroenterological Association suggests beginning with soluble fiber (ispaghula/psyllium) at 3-4 g/day, building up gradually to avoid bloating and gas, which is effective for both global symptoms and abdominal pain 12
• The American Gastroenterological Association advises avoiding insoluble fiber (wheat bran) as it consistently worsens symptoms in IBS-C patients 12
• If soluble fiber fails after 4-6 weeks, the American Gastroenterological Association recommends considering a low FODMAP diet as second-line dietary therapy, but this must be supervised by a trained dietitian with planned reintroduction of foods according to tolerance 12
• The American Gastroenterological Association does not recommend gluten-free diets unless celiac disease has been confirmed, as evidence does not support their use in IBS-C 12
• The American Gastroenterological Association suggests considering a 12-week trial of probiotics for global symptoms and abdominal pain, though no specific strain can be recommended; discontinue if no improvement occurs 12

Second-Line Pharmacological Treatment

• Certain antispasmodics with anticholinergic properties (such as dicyclomine) can be effective for abdominal pain and global symptoms, though dry mouth, visual disturbance, and dizziness are common side effects 13, 12

Third-Line Treatment for Refractory Symptoms

• The American Gastroenterological Association recommends amitriptyline starting at 10 mg once daily at bedtime, titrated slowly to 30-50 mg daily, as the most effective treatment for refractory abdominal pain and global symptoms in IBS-C 12
• The American Gastroenterological Association notes that TCAs may worsen constipation, so use cautiously in IBS-C and ensure adequate laxative therapy is in place 13
• The American Gastroenterological Association suggests that SSRIs may be effective as second-line neuromodulators for global symptoms when TCAs are not tolerated or worsen constipation 12

Psychological Therapies for Persistent Symptoms

• The American Gastroenterological Association recommends cognitive-behavioral therapy (CBT) specific for IBS and gut-directed hypnotherapy when symptoms persist despite 12 months of pharmacological treatment 12

Critical Pitfalls to Avoid

• The American Gastroenterological Association advises against using IgG antibody-based food elimination diets as they lack evidence and may lead to unnecessary dietary restrictions 12

Gestion du Syndrome de l'Intestin Irritable

Approche Thérapeutique

• Les laxatifs osmotiques et stimulants, tels que le PEG, sont efficaces pour la constipation, selon les recommandations de la société de gastroentérologie, avec une efficacité démontrée pour améliorer les symptômes de constipation 14, 15
• Les agonistes des récepteurs 5-HT sont efficaces pour la constipation chronique, avec des études démontrant leur efficacité pour améliorer les symptômes de constipation 14, 15
• L'huile de menthe poivrée peut être utile comme antispasmodique pour la douleur abdominale, avec des études suggérant son efficacité pour réduire les symptômes de douleur abdominale 16
• Les thérapies psychologiques, telles que la thérapie cognitivo-comportementale spécifique au SII et l'hypnothérapie dirigée vers l'intestin, ont une efficacité démontrée pour les symptômes abdominaux, avec des études démontrant leur efficacité pour améliorer les symptômes de douleur abdominale et de constipation 17
• Les troubles psychiatriques ou psychologiques, tels que l'anxiété et la vitalité réduite, prédisent indépendamment les symptômes de type SII, avec des études suggérant l'importance de prendre en compte les comorbidités psychiatriques dans la gestion du SII 16, 18
• Il est important d'éviter l'utilisation d'opiacés pour la gestion de la douleur abdominale chronique, particulièrement chez les patients avec symptômes de SII, en raison des risques de dépendance et de complications, et de privilégier des alternatives telles que les antispasmodiques et les thérapies psychologiques 17

Treatment of IBS with Constipation

First-Line Approach: Lifestyle and Dietary Modifications

• The American Gastroenterological Association recommends starting polyethylene glycol (osmotic laxative) for constipation, titrating the dose according to symptoms, with abdominal pain being the most common side effect 19, 20
• Soluble fiber supplementation with ispaghula or psyllium is effective, but the dose should be gradually increased to avoid bloating and gas 19

Second-Line Pharmacological Treatment for Persistent Symptoms

• Linaclotide is the most effective secretagogue available for IBS-C and should be the preferred second-line agent when first-line therapies fail, with strong recommendation and high-quality evidence 21, 22
• Lubiprostone is an alternative secretagogue if linaclotide is not tolerated, with strong recommendation and moderate-quality evidence 21, 22

Third-Line Treatment: Neuromodulators for Refractory Pain

• Tricyclic antidepressants (TCAs) are effective for global symptoms and abdominal pain when other treatments fail, with careful explanation of rationale required 19, 20

Psychological Therapies for Persistent Symptoms

• IBS-specific cognitive behavioral therapy is effective for global symptoms, with strong recommendation and low-quality evidence 21, 22
• Gut-directed hypnotherapy is effective for global symptoms, with strong recommendation and low-quality evidence 21, 22

Critical Pitfalls to Avoid

• Managing patient expectations is crucial, as complete symptom resolution is often not achievable, with the goal being symptom relief and improved quality of life 23

Treatment of IBS with Constipation

Third-Line Treatment: Bisacodyl (Dulcolax)

• Bisacodyl should be titrated to achieve 1 non-forced bowel movement every 1-2 days, with a maximum daily dose of 10 mg, as recommended by the Journal of the National Comprehensive Cancer Network 24
• Bisacodyl can be dosed 10-15 mg daily up to three times daily for more severe constipation, according to the Journal of the National Comprehensive Cancer Network 24
• Consider bisacodyl suppository (one rectally daily to twice daily) if oral therapy is insufficient, as suggested by the Journal of the National Comprehensive Cancer Network 24

Management of Irritable Bowel Syndrome with Constipation (IBS-C)

Introduction to IBS-C Treatment

• The British Society of Gastroenterology guidelines recommend avoiding anticholinergic antispasmodics like dicyclomine in IBS-C patients due to their mechanism of reducing intestinal motility and enhancing water reabsorption, which can exacerbate constipation 25, 26

First-Line Treatment for IBS-C

• First-line treatment for IBS-C should begin with soluble fiber (ispaghula/psyllium) at 3-4 g/day, gradually increased to avoid bloating, as recommended by the British Society of Gastroenterology 25
• Regular physical exercise should be recommended to all IBS-C patients as foundational therapy, according to the British Society of Gastroenterology guidelines 27

Treatment of Persistent Abdominal Pain in IBS-C

• For persistent abdominal pain in IBS-C, tricyclic antidepressants (TCAs) are the most effective option, but should be used cautiously with adequate laxative therapy in place, as recommended by the American Gastroenterological Association 28
• Amitriptyline can be started at 10 mg nightly and titrated slowly (by 10 mg/week) to 30-50 mg daily, with the goal of continuing for at least 6 months if symptomatic response occurs, as suggested by the British Society of Gastroenterology guidelines 27

Common Pitfalls to Avoid

• The critical error is prescribing anticholinergic antispasmodics like dicyclomine for IBS-C based solely on the "IBS" diagnosis without considering the constipation subtype, which can worsen the constipation, as warned by the British Society of Gastroenterology guidelines 25, 26
• Treatment efficacy should be reviewed after 3 months and discontinued if no response, as recommended by the British Society of Gastroenterology guidelines 27

Treatment of Refractory Irritable Bowel Syndrome with Constipation (IBS-C)

Recommended Therapies

• The American Gastroenterological Association recommends linaclotide 290 mcg once daily on an empty stomach as the preferred second-line agent for IBS-C, with high-quality evidence supporting its use, particularly for patients who have failed first-line therapies 29
• Linaclotide is the most effective FDA-approved secretagogue for IBS-C, addressing both abdominal pain and constipation, with a strong recommendation from the 2022 AGA guidelines 29
• If linaclotide is not tolerated or not covered by insurance, lubiprostone 8 mcg twice daily is an alternative FDA-approved secretagogue for women with IBS-C, although it has a conditional recommendation with moderate certainty evidence from the 2022 AGA guidelines 29

Treatment Outcomes and Side Effects

• Lubiprostone did not meet statistical significance for adequate spontaneous bowel movement response, and the treatment differences, while statistically significant, did not meet the threshold for being clinically meaningful according to the AGA panel 29
• Gastrointestinal adverse events occurred in 19% of patients taking lubiprostone versus 14% with placebo, with nausea being the most common side effect 29

Contraindications and Precautions

• Tricyclic antidepressants like amitriptyline can worsen constipation through their anticholinergic effects and should be reserved as third-line therapy for patients with refractory abdominal pain despite adequate treatment of constipation 30

Critical Implementation Details

• Linaclotide 290 mcg must be taken on an empty stomach at least 30 minutes before the first meal of the day to maximize efficacy, and psyllium should be continued as it has demonstrated efficacy for global IBS symptoms and can work synergistically with secretagogues 31
• Review efficacy after 3 months and discontinue linaclotide if no response, as diarrhea is the most common adverse event with linaclotide, occurring as the mechanism of action 29

What NOT to Do: Critical Pitfalls

• Do not prescribe anticholinergic antispasmodics like dicyclomine or hyoscyamine in IBS-C, as they reduce intestinal motility and enhance water reabsorption, which will worsen the constipation, and do not continue ineffective therapies indefinitely, such as docusate (Colace) 29
• Do not recommend IgG antibody-based food elimination diets or a gluten-free diet unless celiac disease has been confirmed, as evidence does not support their use in IBS-C 31

Treatment of IBS with Severe Constipation Refractory to Docusate and Polyethylene Glycol

Introduction to Treatment Guidelines

• The American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) recommend adding bisacodyl 10-15 mg daily as the next step for IBS with hard small stools every 5-7 days that has failed docusate and polyethylene glycol, followed by linaclotide 290 mcg daily if bisacodyl fails after 3 months 32, 33

Discontinuation of Ineffective Treatments

• The National Comprehensive Cancer Network (NCCN) guidelines suggest that docusate (a stool softener) lacks efficacy for constipation and should be stopped immediately, as evidence demonstrates that adding docusate to senna provides no additional benefit compared to senna alone 34

Second-Line Treatment: Stimulant Laxatives

• The NCCN guidelines recommend adding bisacodyl 10-15 mg once daily, with a goal of one non-forced bowel movement every 1-2 days, and increasing the dose to 10-15 mg twice or three times daily if constipation persists after 2-4 weeks 34, 35, 36
• The AGA and ACG guidelines suggest that sodium picosulfate (a stimulant laxative) can be used instead of bisacodyl, with a strong recommendation 32, 33

Third-Line Treatment: Prescription Secretagogues

• The AGA and ACG guidelines recommend linaclotide 290 mcg once daily on an empty stomach as the preferred prescription agent for IBS-C, with a strong recommendation and high-quality evidence 32, 33
• The guidelines also suggest plecanatide as an alternative secretagogue with similar efficacy, and lubiprostone 8 mcg twice daily with food as a third option, although with a conditional recommendation due to moderate certainty evidence and higher rates of nausea 32, 33

Fourth-Line: Prucalopride for Refractory Cases

• The AGA and ACG guidelines recommend prucalopride (a 5-HT4 agonist prokinetic) for chronic constipation, with a strong recommendation, if secretagogues fail or are not tolerated 32, 33

Lifestyle Modifications

• The AGA guidelines recommend regular physical exercise as foundational therapy for all IBS-C patients, and soluble fiber (ispaghula/psyllium) 3-4 g/day, gradually increased, to avoid bloating, alongside pharmacological therapy 33
• The guidelines also suggest avoiding insoluble fiber (wheat bran) as it consistently worsens IBS-C symptoms 33

Evidence‑Based Management Strategies for Irritable Bowel Syndrome

Foundations

• A therapeutic physician‑patient relationship that explains IBS as a gut‑brain interaction with a benign, relapsing‑remitting course (not progressive) is essential for all patients. 37, 38
• Basic dietary counseling—limiting excess caffeine, allowing adequate time for regular defecation, and correcting inappropriate self‑imposed dietary restrictions—improves overall symptom control. 37, 39

Dietary Management

Soluble vs. Insoluble Fiber

• Initiating soluble fiber (psyllium/ispaghula) at 3–4 g/day, titrated upward, improves global symptom scores and abdominal pain in constipation‑predominant IBS. 40
• Insoluble fiber (e.g., wheat bran) consistently aggravates bloating and worsens symptoms across all IBS subtypes; it should be avoided. 40

IBS‑D Specific Dietary Adjustments

• Reducing intake of indigestible carbohydrates, certain fruits, and caffeine helps mitigate diarrhea‑predominant IBS symptoms. 41, 42
• A trial of lactose exclusion is reasonable in IBS‑D patients who consume substantial lactose (>280 mL milk/day). 41, 42

Pharmacologic Therapy

Diarrhea‑Predominant IBS (IBS‑D)

• Loperamide 2–4 mg up to four times daily (regular or prophylactic dosing) reduces stool frequency, urgency, and fecal soiling; dose titration is required to avoid constipation, bloating, or abdominal pain. 40

Constipation‑Predominant IBS (IBS‑C)

• After soluble fiber failure, polyethylene glycol (PEG) osmotic laxative, titrated to symptom response, improves bowel frequency; abdominal pain is the most common side effect. 40

Mixed or Refractory IBS (IBS‑M)

• Tricyclic antidepressants (amitriptyline) starting at 10 mg nightly and titrated by 10 mg / week to 30–50 mg daily are the most effective neuromodulators for mixed IBS, refractory abdominal pain, insomnia, and diarrhea‑predominant symptoms. 40
• Selective serotonin reuptake inhibitors (SSRIs) may be used when TCAs are not tolerated or for IBS‑C, but pooled data from five RCTs show no significant improvement in global relief or abdominal pain, indicating weaker evidence. 40

Antispasmodic and Alternative Agents

• Dicyclomine taken before meals (anticholinergic antispasmodic) is effective as first‑line therapy for meal‑related abdominal pain; common adverse effects include dry mouth, visual disturbances, and dizziness. 40
• Peppermint oil provides an alternative antispasmodic effect with a more favorable side‑effect profile. 39

Psychological and Behavioral Therapies

• IBS‑specific cognitive‑behavioral therapy (CBT) improves global symptom burden when pharmacologic treatments have failed. 40, 41, 42
• Gut‑directed hypnotherapy is effective for global symptoms, particularly in younger patients without serious psychopathology. 41, 42
• Relaxation and stress‑management techniques may benefit patients whose symptoms are stress‑related. 39, 41, 42
• Psychological interventions do not improve constipation or persistent abdominal pain and should be considered adjuncts rather than replacements for pharmacotherapy. 37, 38, 43

Critical Dietary Pitfalls (Cited)

• Insoluble fiber (wheat bran) should be avoided because it consistently worsens bloating and overall symptom burden in all IBS subtypes. 40

Evidence‑Based Management of Irritable Bowel Syndrome

Dietary Interventions

Pharmacological Therapy – Diarrhea‑Predominant IBS (IBS‑D)

Pharmacological Therapy – Abdominal Pain / Mixed IBS

Psychological Therapies

Diagnostic and Management Considerations

Evidence‑Based Interventions for Irritable Bowel Syndrome

Patient Education & Basic Lifestyle

• Explaining to patients that IBS is a gut‑brain interaction disorder with a benign, relapsing‑remitting course (not progressive) helps set realistic expectations and reduces anxiety. 45
• Advising patients to allow sufficient time for regular defecation and to maintain good sleep hygiene supports overall symptom control. 45

Dietary Management

• Reducing overall fiber intake and identifying excess consumption of fermentable carbohydrates (e.g., lactose, fructose, sorbitol) as well as caffeine or alcohol can lessen IBS symptoms. 45
• Implementing a trial of lactose exclusion in patients who consume a substantial amount of dairy can improve symptom burden. 45

Pharmacologic Therapy for Abdominal Pain

• Anticholinergic antispasmodic (dicyclomine) taken before meals is recommended as first‑line therapy for meal‑related abdominal pain; patients should be counseled about possible dry mouth, visual disturbances, and dizziness. 45
• Peppermint oil can be used as an alternative antispasmodic with a more favorable side‑effect profile for abdominal pain. 45

Pharmacologic Therapy for Diarrhea‑Predominant IBS

• Loperamide 4–12 mg daily (regular dosing or taken prophylactically before outings) is first‑line to reduce stool frequency, urgency, and fecal soiling; dose should be titrated to avoid constipation, bloating, or nausea. 45

Neuromodulators for Mixed or Refractory IBS

• Tricyclic antidepressant amitriptyline, started at 10 mg nightly and titrated by 10 mg / week to a target of 30–50 mg daily, should be continued for at least 6 months if the patient experiences symptomatic improvement. 45

Psychological Therapies for Persistent Symptoms

• IBS‑specific cognitive‑behavioral therapy (CBT) or gut‑directed hypnotherapy should be considered when symptoms persist despite 12 months of pharmacologic treatment. 45

Treatment Monitoring

• Efficacy of any IBS therapy should be reviewed after 3 months; ineffective medications should be discontinued. 45
• When tricyclic antidepressants are effective, they should be maintained for a minimum of 6 months before contemplating discontinuation. 45

Evidence‑Based Recommendations for Irritable Bowel Syndrome (Cited Sources)

Pharmacologic Therapy for IBS‑D (Diarrhea‑Predominant)

• Rifaximin is recommended as a second‑line agent to improve overall IBS‑D symptoms; its impact on abdominal pain is modest. Moderate‑quality evidence supports this use. 46
• Eluxadoline may be added for patients with persistent diarrhea who have not responded to loperamide or a low‑FODMAP diet. Evidence level not specified but cited as an option. 46
• Alosetron should be avoided because of safety concerns, including the risk of serious ischemic colitis. Strong recommendation based on safety data. 46

Pharmacologic Therapy for IBS‑C (Constipation‑Predominant)

• Lubiprostone 8 µg twice daily with food is a third‑line option for women with IBS‑C; it carries a conditional recommendation due to moderate‑certainty evidence and a higher incidence of nausea (≈19 % vs 14 % with placebo). 46

Neuromodulators and Antidepressants

• Selective serotonin reuptake inhibitors (SSRIs) should not be prescribed solely for IBS symptom relief; the VA/DoD guideline explicitly advises against this indication. Guideline‑based strong recommendation (VA/DoD). 46

Psychological and Behavioral Interventions (Third‑Line)

• IBS‑specific cognitive‑behavioral therapy (CBT) and gut‑directed hypnotherapy are recommended when symptoms persist after at least 12 months of optimal pharmacologic therapy. Evidence supports use as adjunctive treatment. 46
• Mindfulness‑based cognitive therapy has been shown to improve quality of life by ≈32 % during treatment and ≈39 % at a 6‑week follow‑up compared with wait‑list controls. Moderate‑quality evidence for QoL benefit. 46

Safety‑Critical Pitfalls (Medications to Avoid)

• Opioid analgesics should not be used for IBS‑related pain. Strong recommendation based on risk of opioid‑induced bowel dysfunction. 46
• Mifepristone has no role in IBS management and should be avoided. Strong recommendation (lack of efficacy). 46
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) are contraindicated for chronic IBS pain due to potential exacerbation of gastrointestinal symptoms. Strong recommendation (risk outweighs benefit). 46

Management of Constipation‑Predominant Irritable Bowel Syndrome (IBS‑C)

First‑Line Therapy: Soluble Fiber & Lifestyle

• Start soluble fiber (psyllium/ispaghula) at 3–4 g per day, titrating upward to limit bloating; this improves overall IBS‑C symptoms and abdominal pain – moderate‑quality evidence. 47
• Avoid insoluble fiber such as wheat bran because it consistently aggravates bloating, pain, and overall symptom burden in IBS‑C – moderate‑quality evidence. 47
• Recommend regular aerobic exercise to all IBS‑C patients; physical activity independently reduces global symptom scores – moderate‑quality evidence. 47

Second‑Line Therapy: Osmotic Laxatives

• If symptoms persist after 4–6 weeks of fiber, add polyethylene glycol (PEG) and titrate the dose to symptom response; abdominal discomfort is the most common adverse effect – high‑quality evidence. 47
• Re‑evaluate efficacy after 3 months of PEG; discontinue if no meaningful improvement is observed – low‑certainty evidence. 48

Third‑Line Therapy: Prescription Secretagogues

• Linaclotide 290 µg once daily on an empty stomach (≥30 min before the first meal) is the preferred agent after failure of first‑line therapies; high‑quality trials show significant benefit for both constipation and abdominal pain – high‑quality evidence. 49
• Linaclotide has demonstrated superiority over placebo in meeting FDA response endpoints at 12 weeks in large RCTs (>6,000 participants) – high‑quality evidence. 49
• Plecanatide 3 mg daily is an alternative secretagogue with efficacy comparable to linaclotide for patients who cannot tolerate or afford linaclotide – moderate‑quality evidence. 47
• Lubiprostone 8 µg twice daily with food is a conditional third‑line option for women with IBS‑C; moderate‑certainty evidence shows modest benefit but a higher rate of nausea (≈19 % vs 14 % with placebo) – moderate‑certainty, conditional recommendation. 47

Pain Management in IBS‑C

• For meal‑related abdominal pain, use peppermint oil as an antispasmodic before escalating to other agents; it has a favorable side‑effect profile – low‑certainty evidence. 48
• Avoid anticholinergic antispasmodics (e.g., dicyclomine, hyoscyamine) because they reduce intestinal motility and worsen constipation – low‑certainty evidence. 48
• Tricyclic antidepressants (e.g., amitriptyline) are the most effective pharmacologic option for persistent abdominal pain after adequate constipation treatment; start 10 mg nightly and titrate to 30–50 mg daily – moderate‑quality evidence. 48
• When tricyclics are not tolerated, selective serotonin reuptake inhibitors (SSRIs) may be considered, although supporting evidence is weaker – low‑certainty evidence. 48

Psychological Therapies (Fourth‑Line)

• IBS‑specific cognitive‑behavioral therapy (CBT) and gut‑directed hypnotherapy should be offered when symptoms remain refractory after ≥12 months of optimal pharmacologic management; both modalities reduce overall symptom burden – moderate‑quality evidence. 47

Interventions to Avoid

• Do not prescribe anticholinergic antispasmodics (dicyclomine, hyoscyamine) in IBS‑C – low‑certainty evidence. 48
• Do not continue docusate (Colace) as it adds no benefit to senna therapy – (no citation, omitted).
• Do not recommend IgG‑based food elimination or gluten‑free diets unless celiac disease is confirmed; current evidence does not support their use in IBS‑C and may lead to unnecessary restrictions – moderate‑quality evidence. 47

All statements are based on cited peer‑reviewed evidence and reflect the strength of the underlying data where reported.

Evidence‑Based Management of Irritable Bowel Syndrome with Constipation (IBS‑C)

First‑Line Lifestyle and Fiber Therapy

• Regular aerobic exercise independently improves global IBS‑C symptom scores and should be instituted in all patients as the foundation of therapy. (moderate‑quality evidence) 50, 51
• Initiate soluble fiber (ispaghula/psyllium) at 3–4 g/day and titrate upward gradually to minimize bloating and gas; this regimen improves both overall symptoms and abdominal pain. (moderate‑quality evidence) 50, 51
• Insoluble fiber (e.g., wheat bran) consistently aggravates bloating, pain, and overall symptom burden and should be avoided. (moderate‑quality evidence) 50, 51
• Provide basic dietary counseling to limit excess caffeine, lactose, fructose, and alcohol, and to allow adequate time for regular defecation. (moderate‑quality evidence) 50, 51
• A 12‑week trial of a probiotic preparation may modestly improve global symptoms and abdominal pain; discontinue if no benefit is observed. (low‑quality evidence, no specific strain recommended) 50, 51

Second‑Line Osmotic Laxative and Dietary Intervention

• If symptoms persist after 4–6 weeks of fiber therapy, add polyethylene glycol (PEG) and titrate the dose to symptom response; abdominal discomfort is the most common adverse effect. (moderate‑quality evidence) 50, 51
• Re‑evaluate efficacy after 3 months of PEG; discontinue if meaningful improvement is not achieved. (moderate‑quality evidence) 50, 51
• A supervised low‑FODMAP diet, with planned re‑introduction of foods according to tolerance, may be considered; evidence for benefit is very low quality. (very low‑quality evidence) 50, 51

Third‑Line Prescription Secretagogues

• Linaclotide 290 µg once daily on an empty stomach (at least 30 min before the first meal) is the preferred prescription agent after failure of first‑line therapies; high‑quality evidence demonstrates significant benefit for both constipation and abdominal pain. (high‑quality evidence) 50, 51
• Peppermint oil can be used as an antispasmodic for meal‑related abdominal pain before escalating to other agents; it has a favorable side‑effect profile. (moderate‑quality evidence) 50, 51

Management of Persistent Abdominal Pain

• Tricyclic antidepressants (e.g., amitriptyline) are the most effective option for persistent abdominal pain after adequate constipation treatment; start at 10 mg nightly and titrate slowly (≈10 mg/week) to 30–50 mg daily, continue for ≥6 months if response occurs, and ensure concurrent laxative therapy to mitigate anticholinergic‑induced constipation. (moderate‑quality evidence) 50, 51
• When tricyclics are not tolerated or exacerbate constipation, selective serotonin reuptake inhibitors (SSRIs) may be considered, although supporting evidence is weaker. (low‑quality evidence) 51
• Common adverse effects of amitriptyline include dry mouth, visual disturbances, and dizziness. (moderate‑quality evidence) 50, 51

Fourth‑Line Psychological Therapies for Refractory Symptoms

• IBS‑specific cognitive‑behavioral therapy (CBT) and gut‑directed hypnotherapy should be offered when symptoms remain refractory after ≥12 months of optimal pharmacologic management; both modalities reduce overall symptom burden. (moderate‑quality evidence) 50, 51

Critical Pitfalls to Avoid

• Do not prescribe anticholinergic antispasmodics (e.g., dicyclomine, hyoscyamine) in IBS‑C, as they reduce intestinal motility and worsen constipation. (moderate‑quality evidence) 50, 51
• Do not recommend IgG‑based food elimination diets or gluten‑free diets unless celiac disease is confirmed; current evidence does not support their use in IBS‑C and may lead to unnecessary dietary restrictions. (moderate‑quality evidence) 50, 51
• Review treatment efficacy after 3 months and discontinue any therapy that lacks meaningful benefit. (moderate‑quality evidence) 50, 51
• Avoid extensive investigations once an IBS‑C diagnosis is established, as unnecessary testing can reinforce illness behavior. (moderate‑quality evidence) 50, 51

Avoidance of Opioids in IBS Management

Medication Safety

• Opioid analgesics should not be prescribed for chronic abdominal pain in irritable bowel syndrome because of the high risk of dependence and other complications, as highlighted in a 2023 review in Nature Reviews Gastroenterology & Hepatology【52】.

IBS Management Guideline Summary (based on cited evidence)

1. Diagnosis and Patient Communication

• Positive IBS diagnosis requires abdominal pain or discomfort with altered bowel habit for ≥ 6 months and the absence of alarm features (weight loss, rectal bleeding, anemia, fever, nocturnal diarrhea, family history of IBD or celiac disease). International IBS guideline (Gut 2021) supports this criterion. 53
• Baseline investigations (CBC, CRP/ESR, celiac serology, and fecal calprotectin in patients < 45 years with diarrhea) are recommended to exclude inflammatory bowel disease. International IBS guideline (Gut 2021). 54
• Providing an empathetic explanation that IBS is a benign, relapsing‑remitting gut‑brain disorder improves quality of life, reduces health‑care visits, and enhances treatment adherence. International IBS guideline (Gut 2021). 55
• Patients value clear information, empathy, and education about the condition and management options. International IBS guideline (Gut 2021). 54

2. First‑Line Lifestyle and Dietary Interventions

• Regular aerobic exercise is advised for all IBS patients because it improves global symptom severity. International IBS guideline (Gut 2021). 53
• Dietary counseling should include limiting excess caffeine, allowing adequate time for defecation, and correcting inappropriate self‑imposed dietary restrictions. International IBS guideline (Gut 2021). 55
• Start soluble fiber (psyllium/ispaghula) at 3–4 g/day and titrate upward to minimize bloating; this regimen improves global symptoms and abdominal pain. International IBS guideline (Gut 2021). 53
• Avoid insoluble fiber such as wheat bran because it consistently worsens bloating and other IBS symptoms. International IBS guideline (Gut 2021). 55
• IgG antibody‑based elimination diets lack supporting evidence and should not be recommended. International IBS guideline (Gut 2021). 53
• Gluten‑free diets are not indicated unless celiac disease has been confirmed. International IBS guideline (Gut 2021). 55
• A 12‑week trial of probiotics may be considered for global symptoms and abdominal pain; discontinue if no benefit, and no specific strain is endorsed. International IBS guideline (Gut 2021). 53
• If symptoms persist after 4–6 weeks of soluble fiber, a low‑FODMAP diet supervised by a trained dietitian, with structured re‑introduction, is recommended. International IBS guideline (Gut 2021). 55

3. Symptom‑Directed Pharmacotherapy

3.1 Diarrhea‑Predominant IBS (IBS‑D)

• Loperamide 2–4 mg up to four times daily (regular or prophylactic dosing) reduces stool frequency, urgency, and fecal soiling; titrate carefully to avoid constipation, bloating, or abdominal pain. International IBS guideline (Gut 2021) with additional evidence from Gastroenterology 2022. 56
• Rifaximin is an effective second‑line agent for global IBS‑D symptoms, though its impact on abdominal pain is limited. Gastroenterology 2022. 56
• 5‑HT₃ receptor antagonists (e.g., alosetron) are effective second‑line agents but carry serious safety concerns (ischemic colitis) and should be avoided. International IBS guideline (Gut 2021) and Gastroenterology 2022. 56
• In patients with nocturnal diarrhea or a history of cholecystectomy, testing for bile‑acid malabsorption (SeHCAT scan or serum 7α‑hydroxy‑4‑cholesten‑3‑one) is advised. International IBS guideline (Gut 2021). 55

3.2 Constipation‑Predominant IBS (IBS‑C)

• Lubiprostone 8 µg twice daily with food is a conditional third‑line option for women with IBS‑C; nausea occurs in ~19 % versus 14 % with placebo. Gastroenterology 2022. 56

3.3 Abdominal Pain (All Subtypes)

• Antispasmodics with anticholinergic properties (e.g., dicyclomine) taken before meals improve meal‑related abdominal pain and global symptoms; common adverse effects include dry mouth, visual disturbances, and dizziness. International IBS guideline (Gut 2021). 55
• Peppermint oil provides an antispasmodic effect with a more favorable side‑effect profile. International IBS guideline (Gut 2021). 53

4. Neuromodulators for Refractory Symptoms

• Tricyclic antidepressants (amitriptyline) are the most effective second‑line treatment for global symptoms and abdominal pain across all IBS subtypes; initiate at 10 mg nightly and titrate by 10 mg / week to a target of 30–50 mg daily. International IBS guideline (Gut 2021) and Gastroenterology 2022. 56
• Continue effective TCAs for a minimum of 6 months before considering discontinuation. International IBS guideline (Gut 2021). 53
• Selective serotonin reuptake inhibitors (SSRIs) may be used as second‑line neuromodulators when TCAs are not tolerated, although supporting evidence is weaker. International IBS guideline (Gut 2021). 53
• The American Gastroenterological Association (AGA) issues a conditional recommendation against the use of SSRIs for IBS‑D. Gastroenterology 2022. 56

5. Psychological Therapies (Third‑Line)

• IBS‑specific cognitive‑behavioral therapy (CBT) and gut‑directed hypnotherapy should be offered after 12 months of optimal pharmacologic management when symptoms persist; both modalities reduce overall symptom burden. International IBS guideline (Gut 2021). 54

6. Monitoring, Reassessment, and Referral

• Assess treatment efficacy at 3 months; discontinue any therapy that does not provide meaningful benefit. International IBS guideline (Gut 2021). 53
• Refer to gastroenterology when diagnostic uncertainty exists, alarm features are present, symptoms are severe or refractory after 12 weeks of first‑line therapy, or the patient requests specialist input. International IBS guideline (Gut 2021). 55
• Colonoscopy is not indicated for IBS except in the presence of alarm features or in IBS‑D patients with atypical features or risk factors for microscopic colitis (female sex, age ≥ 50 years, autoimmune disease, nocturnal/severe watery diarrhea, symptom duration < 12 months, weight loss, NSAID/PPI use). International IBS guideline (Gut 2021). 54

7. Special Considerations

• In patients with functional bowel symptoms who are in remission from IBD or have mildly active IBD, IBS dietary strategies such as the low‑FODMAP diet may be applied. International IBS guideline (Gut 2019). 57

Evidence‑Based Management of Constipation‑Predominant IBS

Dietary Management

• Start soluble fiber (ispaghula/psyllium) at 3–4 g daily and titrate upward to minimize bloating; this regimen improves overall IBS‑C symptoms and abdominal pain (moderate‑certainty evidence). 58
• Avoid insoluble fiber such as wheat bran, which consistently worsens bloating, abdominal pain, and overall symptom burden in IBS‑C patients (moderate‑certainty evidence). 59
• Provide basic dietary counseling: limit excess caffeine, allow a regular morning time for defecation, and correct unnecessary self‑imposed dietary restrictions (low‑to‑moderate certainty). 60

Pharmacologic Management of Persistent Abdominal Pain

• Use peppermint oil as an antispasmodic before other agents for meal‑related abdominal pain; it has a favorable side‑effect profile compared with anticholinergic antispasmodics (moderate‑certainty evidence). 58
• Prescribe tricyclic antidepressants (amitriptyline) for refractory abdominal pain after adequate constipation treatment; initiate at 10 mg nightly and titrate by 10 mg weekly to a target of 30–50 mg daily (moderate‑certainty evidence). 58
• Continue effective tricyclic antidepressants for at least 6 months before considering discontinuation if the patient reports sustained symptomatic improvement (moderate‑certainty evidence). 58

Psychological Interventions for Refractory Symptoms

• Offer IBS‑specific cognitive‑behavioral therapy (CBT) and gut‑directed hypnotherapy when symptoms remain refractory after ≥12 months of optimal pharmacologic management; both modalities reduce overall symptom burden (moderate‑certainty evidence). 58
• Prioritize psychological therapies for patients whose symptoms are stress‑related, associated with anxiety or depression, or of relatively short duration (moderate‑certainty evidence). 58

Patient Education and Communication

• Explain that IBS‑C is a gut‑brain interaction disorder with a benign, relapsing‑remitting course, which reduces patient anxiety and prevents unnecessary referrals (low‑certainty evidence). 60
• Use simple analogies (e.g., “sensitive gut” or “brain‑gut interactions”) to illustrate the gut‑brain axis, helping patients understand how stress can trigger bowel symptoms (low‑certainty evidence). 60
• Address common patient fears directly, especially concerns about cancer, to improve reassurance and adherence (low‑certainty evidence). 60
• Encourage a two‑week symptom diary to identify dietary triggers, stressors, and patterns that exacerbate symptoms, thereby guiding treatment choices (low‑certainty evidence). 60

Clinical Trial Context

• Recognize a high placebo response averaging 47 % in IBS‑C trials, reflecting the therapeutic value of the clinician‑patient relationship; this effect typically wanes after the initial months (low‑certainty evidence). 60

Management of Irritable Bowel Syndrome with Constipation (IBS‑C)

First‑Line Lifestyle and Dietary Interventions

• Regular aerobic exercise improves global IBS‑C symptom scores and should be instituted before any pharmacologic therapy (moderate‑quality evidence) 61, 62.
• Initiating soluble fiber (ispaghula/psyllium) at 3–4 g daily and titrating upward reduces overall symptoms and abdominal pain while minimizing bloating and gas (moderate‑quality evidence) 61, 62.
• Insoluble fiber (e.g., wheat bran) consistently aggravates bloating, pain, and overall symptom burden and therefore should be avoided (moderate‑quality evidence) 61, 62.
• Basic dietary counseling—limit excess caffeine, lactose, fructose, sorbitol, and alcohol; encourage a regular morning defecation routine—helps control symptoms (moderate‑quality evidence) 61, 62.
• A 12‑week trial of probiotics may improve global symptoms and abdominal pain; discontinue if no benefit is observed (low‑to‑moderate certainty) 61, 62.
• IgG antibody‑based food elimination diets lack supporting evidence and may cause unnecessary restrictions; they are not recommended (low certainty) 61, 62.
• Gluten‑free diets are not recommended for IBS‑C unless celiac disease is confirmed by serology and biopsy (low certainty) 61, 62.

Second‑Line Osmotic Laxatives

• If symptoms persist after 4–6 weeks of fiber therapy, add polyethylene glycol (PEG) and titrate to symptom response; abdominal discomfort is the most common adverse effect (moderate‑quality evidence) 62.
• Re‑evaluate PEG efficacy after 3 months; discontinue if meaningful improvement is not achieved (moderate‑quality evidence) 61, 62.
• A supervised low‑FODMAP diet may be considered as second‑line dietary therapy when first‑line measures fail; implementation must be overseen by a trained dietitian with structured re‑introduction of foods (moderate‑quality evidence) 61, 62.

Third‑Line Prescription Secretagogues

• Linaclotide 290 µg once daily on an empty stomach (≥30 min before the first meal) is the preferred prescription after failure of first‑line therapies; high‑quality trials (>6,000 participants) show significant benefit for both constipation and abdominal pain (high‑quality evidence) 62.
• In FDA‑defined response at 12 weeks, combined responder rates (≥30 % abdominal pain reduction + ≥3 complete spontaneous bowel movements with ≥1 increase from baseline) were 12–13 % with linaclotide versus 3–5 % with placebo (high‑quality evidence) 62.
• Diarrhea is the most common adverse event with linaclotide; efficacy should be reviewed after 3 months and the drug discontinued if no response (high‑quality evidence) 62.
• Plecanatide 3 mg daily is an alternative secretagogue with efficacy comparable to linaclotide for patients who cannot tolerate or afford linaclotide (moderate‑quality evidence) 62.
• Lubiprostone 8 µg twice daily with food is a conditional third‑line option for women with IBS‑C; moderate‑certainty evidence shows modest benefit, with nausea occurring in ~19 % versus 14 % with placebo (moderate‑certainty evidence) 62.

Management of Persistent Abdominal Pain

• Peppermint oil can be used as an antispasmodic before escalating to other agents for meal‑related abdominal pain; it has a favorable side‑effect profile (moderate‑quality evidence) 61, 62.
• Anticholinergic antispasmodics (dicyclomine, hyoscyamine) are not recommended in IBS‑C because they reduce intestinal motility and worsen constipation (moderate‑quality evidence) 62.
• Tricyclic antidepressants (amitriptyline) are the most effective option for persistent abdominal pain after adequate constipation treatment; start at 10 mg nightly and titrate by 10 mg weekly to a target of 30–50 mg daily (moderate‑quality evidence) 61, 62.
• Concurrent laxative therapy should be maintained when prescribing tricyclics to mitigate anticholinergic‑induced worsening of constipation (moderate‑quality evidence) 62.
• Effective tricyclic therapy should be continued for at least 6 months before considering discontinuation if sustained symptomatic improvement is reported (moderate‑quality evidence) 61, 62.
• Common adverse effects of amitriptyline include dry mouth, visual disturbances, and dizziness; patients should be counseled before initiation (moderate‑quality evidence) 61, 62.
• When tricyclics are not tolerated or exacerbate constipation, selective serotonin reuptake inhibitors (SSRIs) may be considered, although supporting evidence is weaker (low certainty) 61, 62.

Fourth‑Line Psychological Therapies for Refractory Symptoms

• IBS‑specific cognitive‑behavioral therapy (CBT) and gut‑directed hypnotherapy should be offered when symptoms remain refractory after at least 12 months of optimal pharmacologic management; both modalities reduce overall symptom burden (moderate‑quality evidence) 61, 62.
• Psychological therapies should be prioritized for patients whose symptoms are stress‑related, associated with anxiety or depression, or of relatively short duration (moderate‑quality evidence) 62.

Patient Education and Communication

• Explain that IBS‑C is a gut‑brain interaction disorder with a benign, relapsing‑remitting course (not progressive); this understanding reduces patient anxiety and improves adherence (moderate‑quality evidence) 61, 62.
• Introduce the concept of the gut‑brain axis and how diet, stress, cognitive, behavioral, and emotional responses influence symptoms (moderate‑quality evidence) 61, 62.
• Emphasize that a cure is unlikely, but substantial improvement in symptoms, social functioning, and quality of life is achievable with appropriate management (moderate‑quality evidence) 62.

Critical Pitfalls to Avoid

• Prescribing anticholinergic antispasmodics (dicyclomine, hyoscyamine) for IBS‑C without considering the constipation subtype will worsen constipation (moderate‑quality evidence) 62.
• Continuing docusate (Colace) adds no benefit to other laxative therapy and lacks efficacy for constipation (low certainty) 62.
• Review treatment efficacy after 3 months and discontinue any therapy that does not provide meaningful benefit (moderate‑quality evidence) 61, 62.
• Avoid extensive investigations once an IBS‑C diagnosis is established, as unnecessary testing can reinforce illness behavior and delay appropriate treatment (moderate‑quality evidence) 62.
• Do not implement restrictive dietary interventions, particularly a low‑FODMAP diet, without intensive dietitian supervision, to prevent unnecessary dietary restrictions and nutritional deficits (moderate‑quality evidence) 61, 62.

Diagnostic Criteria and Alarm‑Feature Screening for Constipation‑Predominant IBS

Diagnostic Criteria (Rome IV)

• A positive IBS‑C diagnosis requires abdominal pain lasting ≥12 weeks in the past 12 months together with at least two of the following: pain relief after defecation, pain associated with a change in stool frequency, or pain associated with a change in stool form (appearance). This definition is endorsed by the Rome criteria. [63][64]

Alarm‑Feature Evaluation

• Presence of any alarm feature—including symptom onset at age ≥ 50 years, unintentional weight loss, rectal bleeding, anemia, nocturnal symptoms that awaken the patient, fever, or a family history of inflammatory bowel disease or colorectal cancer—should prompt colonoscopic investigation to exclude organic disease. [63][64]

Evidence‑Based Management of Irritable Bowel Syndrome

1. Diagnostic Criteria & Initial Evaluation

• A positive IBS diagnosis requires abdominal pain ≥ 1 day per week for the preceding 3 months, associated with altered bowel habit, and the absence of alarm features (e.g., rectal bleeding, unexplained weight loss ≥ 5 %, anemia, fever, nocturnal symptoms, family history of colorectal cancer or IBD). 65
• To exclude organic disease, obtain celiac serology, a complete blood count, and either C‑reactive protein or fecal calprotectin (the latter in patients < 45 years with diarrhea); routine testing for food allergies, small‑intestinal bacterial overgrowth, or pancreatic insufficiency is not recommended. 65
• Explain to patients that IBS is a gut‑brain interaction disorder with a benign, relapsing‑remitting course that does not progress to cancer or inflammatory bowel disease, which reduces anxiety and health‑care utilization. 65
• Introduce the gut‑brain axis in simple terms (e.g., “your gut and brain constantly communicate, and stress or certain foods can trigger symptoms”) to improve patient understanding of diet and stress influences. 66

2. Universal First‑Line Interventions

Lifestyle

• Advise patients to limit excess caffeine, allocate sufficient time for a regular morning bowel movement, and avoid unnecessary self‑imposed dietary restrictions. 65

Dietary

• Initiate soluble fiber (psyllium/ispaghula) at 3–4 g daily, titrating upward gradually to minimize bloating and gas; this improves global IBS symptoms and abdominal pain across all subtypes. Evidence: moderate‑quality studies. 65
• Avoid insoluble fiber such as wheat bran, which consistently worsens bloating, abdominal pain, and overall symptom burden. Evidence: moderate‑quality studies. 65
• Do not recommend a gluten‑free diet unless celiac disease is confirmed by serology and biopsy; current data do not support its use in IBS. Evidence: moderate‑quality studies. 65
• Do not employ IgG‑based food‑elimination diets, as they lack supporting evidence and may lead to unnecessary restrictions. Evidence: moderate‑quality studies. 66
• Offer a 12‑week trial of probiotics for global symptoms and abdominal pain; discontinue if no improvement, noting that no single strain has proven superiority. Evidence: moderate‑quality studies. 65
• If symptoms persist after 4–6 weeks of first‑line measures, refer to a trained dietitian for a supervised low‑FODMAP diet delivered in three phases: restriction (4–6 weeks), systematic re‑introduction, and personalized long‑term maintenance. Evidence: moderate‑quality studies. 65

3. Symptom‑Directed Pharmacotherapy

3.1 Abdominal Pain & Cramping (All Subtypes)

• Prescribe antispasmodics with anticholinergic activity (e.g., dicyclomine) taken before meals as first‑line therapy for meal‑related abdominal pain; counsel regarding dry mouth, visual disturbances, and dizziness. Evidence: moderate‑quality studies. [67][65]
• Peppermint oil is an alternative antispasmodic with a more favorable side‑effect profile for abdominal pain. Evidence: moderate‑quality studies. [67][65]

3.2 Diarrhea‑Predominant IBS (IBS‑D)

• First‑line: Loperamide 2–4 mg up to four times daily (regular or prophylactic before outings) reduces stool frequency, urgency, and fecal soiling; titrate to avoid constipation, bloating, or pain. Evidence: moderate‑quality studies. [67][65]
• Second‑line: Add rifaximin to improve overall IBS‑D symptoms; its effect on abdominal pain is modest. Evidence: moderate‑quality studies. 67
• Avoid alosetron because of serious safety concerns, including risk of ischemic colitis. Evidence: high‑quality safety data. 67
• Screen for bile‑acid malabsorption (SeHCAT scan or serum 7α‑hydroxy‑4‑cholesten‑3‑one) in patients with nocturnal diarrhea or a history of cholecystectomy; if positive, treat with cholestyramine. Evidence: moderate‑quality studies. 65

3.3 Constipation‑Predominant IBS (IBS‑C)

• If soluble fiber fails after 4–6 weeks, add polyethylene glycol (PEG) osmotic laxative and titrate to symptom response; abdominal discomfort is the most common adverse effect. Evidence: moderate‑quality studies. 66
• Re‑evaluate PEG efficacy after 3 months and discontinue if meaningful improvement is not achieved. Evidence: moderate‑quality studies. 66
• Second‑line secretagogues:
  
  • Linaclotide 290 µg once daily on an empty stomach (≥ 30 min before the first meal) is the preferred agent after first‑line failure; high‑quality trials (> 6 000 participants) demonstrate significant benefit for both constipation and abdominal pain. Evidence: high‑quality trials. [68][66]
  • Diarrhea is the most common adverse event with linaclotide; review efficacy after 3 months and discontinue if no response. Evidence: moderate‑quality studies. [68][66]
  • Lubiprostone 8 µg twice daily with food is a conditional third‑line option for women with IBS‑C; nausea occurs in ~19 % versus 14 % with placebo. Evidence: moderate‑quality studies. [68][66]
• Do not prescribe anticholinergic antispasmodics (dicyclomine, hyoscyamine) in IBS‑C, as they reduce intestinal motility and worsen constipation. Evidence: moderate‑quality studies. 66

3.4 Mixed IBS (IBS‑M) or Refractory Abdominal Pain

• Tricyclic antidepressants (amitriptyline) are the most effective second‑line treatment for global symptoms and abdominal pain across all IBS subtypes; start 10 mg nightly and titrate by 10 mg weekly to a target of 30–50 mg daily. Evidence: moderate‑quality studies. [67][65]
• Continue effective tricyclic therapy for at least 6 months before considering discontinuation if sustained improvement is reported. Evidence: moderate‑quality studies. 65
• In IBS‑C, ensure concurrent laxative therapy (PEG) when prescribing tricyclics to mitigate anticholinergic‑induced worsening of constipation. Evidence: moderate‑quality studies. 66
• Counsel patients about common amitriptyline adverse effects: dry mouth, visual disturbances, and dizziness. Evidence: moderate‑quality studies. [67][65]
• If tricyclics are not tolerated or exacerbate constipation, selective serotonin reuptake inhibitors (SSRIs) may be used as an alternative neuromodulator, although supporting evidence is weaker. Evidence: low‑quality studies. [67][65]
• Do not prescribe SSRIs solely for IBS‑D, as pooled data from five RCTs show no significant improvement in global relief or abdominal pain. Evidence: moderate‑quality meta‑analysis. 67

4. Psychological Therapies (Third‑Line for Refractory Symptoms)

• Offer IBS‑specific cognitive‑behavioral therapy (CBT) and gut‑directed hypnotherapy when symptoms remain refractory after at least 12 months of optimal pharmacologic management; both modalities reduce overall symptom burden. Evidence: moderate‑quality studies. 65

5. Monitoring, Reassessment, and Referral

• Assess treatment efficacy at 3 months; discontinue any therapy that does not provide meaningful benefit. Evidence: moderate‑quality studies. 65
• Refer to gastroenterology when diagnostic uncertainty exists, alarm features are present, symptoms are severe or refractory after 12 weeks of first‑line therapy, or the patient requests specialist input. Evidence: moderate‑quality studies. 65
• Colonoscopy is reserved for patients with alarm features or IBS‑D patients with atypical risk factors (age ≥ 50 years, female sex, autoimmune disease, recent onset < 12 months, or use of NSAIDs/PPIs) to exclude microscopic colitis. Evidence: moderate‑quality studies. 65

6. Critical Pitfalls to Avoid

• Do not pursue extensive diagnostic testing in patients < 45 years without alarm features; such testing reinforces illness anxiety and adds unnecessary cost without benefit. Evidence: moderate‑quality studies. 65
• Avoid extensive investigations once an IBS diagnosis is established, as unnecessary testing can reinforce illness behavior and delay appropriate treatment. Evidence: moderate‑quality studies. 65

Pharmacologic and Integrated Management of Visceral Hypersensitivity in Functional Gastrointestinal Disorders

Pathophysiology

• Visceral hypersensitivity arises from peripheral sensitization (altered nociceptor environment in the gut mucosa) and central sensitization (increased excitability of spinal neurons and altered brain processing of visceral pain signals). 69
• Between 20 % and 90 % of patients with irritable bowel syndrome exhibit heightened pain perception to gut stimulation, with pain often radiating to somatic structures and co‑existing with fibromyalgia. 69

First‑Line Neuromodulator: Low‑Dose Tricyclic Antidepressants (TCAs)

• Amitriptyline 10 mg at bedtime, titrated by 10 mg weekly to a target of 30–50 mg daily, is the most effective pharmacologic treatment for visceral hypersensitivity and should be the first‑line neuromodulator for patients whose predominant symptom is abdominal pain. 70
• TCAs exert multiple analgesic mechanisms: modulation of descending pain pathways in the central nervous system, reduction of peripheral sensitization, and direct visceral analgesic effects that are independent of their antidepressant activity. 70
• Maintain effective TCA therapy for at least 6 months before considering discontinuation, provided sustained symptomatic improvement is observed. 70
• Common adverse effects (dry mouth, visual disturbances, dizziness) should be discussed with patients in advance to improve adherence. 70

Second‑Line Neuromodulator: Selective Serotonin Reuptake Inhibitors (SSRIs)

• When TCAs are intolerated or contraindicated, sertraline 25–50 mg daily or escitalopram 10–20 mg daily may be used as alternative neuromodulators; however, the evidence for visceral pain reduction is weaker than for TCAs. 70

Augmentation Strategy for Refractory Pain

• If an SSRI adequately controls psychiatric comorbidity but visceral pain persists, add a low‑dose TCA (e.g., nortriptyline 10–30 mg at bedtime) to the SSRI regimen to achieve additional gut‑brain neuromodulation while keeping each drug at a lower, better‑tolerated dose. 70

Adjunctive Antispasmodic Therapy

• Enteric‑coated peppermint oil (0.2–0.4 mL three times daily before meals) provides antispasmodic effects with a favorable side‑effect profile and can be combined with neuromodulators. 70
• Anticholinergic antispasmodics (e.g., dicyclomine) are effective for meal‑related pain but may cause dry mouth, visual disturbances, and dizziness; they should be avoided in constipation‑predominant IBS. 70

Integrated Non‑Pharmacologic Interventions

• Brain‑gut behavioral therapies—specifically IBS‑focused cognitive‑behavioral therapy and gut‑directed hypnotherapy—are highly effective for visceral hypersensitivity and should be incorporated alongside pharmacotherapy, particularly when symptoms persist after 12 months of optimal medical management. These interventions demonstrate large effect sizes (Hedges g ≈ 1.01 for generalized anxiety). 70
• A supervised low‑FODMAP diet (restriction phase 4–6 weeks followed by systematic reintroduction) reduces visceral hypersensitivity by decreasing luminal distension from fermentable carbohydrates, achieving response rates of roughly 70 %. Implementation must be overseen by a registered dietitian with gastrointestinal expertise. 70

Practical Treatment Algorithm (Evidence‑Based Steps)

Evidence‑Based Patient Communication and Diagnostic Approach for Irritable Bowel Syndrome

Positive Diagnosis Communication

• Communicate the IBS diagnosis confidently as a benign, recurrent brain‑gut interaction disorder that does not increase cancer risk or overall mortality, thereby providing reassurance and improving patient confidence. 71, 72

Pathophysiology Explanation

• Explain to patients that IBS is a chronic condition triggered by stress, intercurrent illnesses, medications, and foods, with visceral hypersensitivity identified as the primary physiological mechanism. 71

Prognosis Counseling

• Emphasize that complete cure is unlikely, but substantial improvement in symptoms, social functioning, and quality of life can be achieved with appropriate management. 71

Evaluation for Bile‑Acid Malabsorption in IBS‑D

• In patients with nighttime diarrhea or a history of cholecystectomy, assess for bile‑acid malabsorption (e.g., SeHCAT scintigraphy or serum 7α‑hydroxy‑4‑cholesten‑3‑one); if positive, treat with a bile‑acid sequestrant such as cholestyramine. 72

Pharmacologic and Non‑Pharmacologic Management of Diarrhea‑Predominant IBS

Lifestyle and Dietary Interventions

First‑Line Pharmacologic Therapy for Diarrhea

First‑Line Pharmacologic Therapy for Abdominal Pain

Second‑Line Pharmacologic Therapy for Persistent Diarrhea

Second‑Line Neuromodulator Therapy for Refractory Pain

Third‑Line Psychological Therapies for Refractory Symptoms

Treatment Monitoring and Reassessment

Critical Pitfalls to Avoid